Related references
Note: Only part of the references are listed.A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP
Paul Coppo et al.
BLOOD (2020)
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
M. Scully et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pathophysiology of thrombotic thrombocytopenic purpura
J. Evan Sadler
BLOOD (2017)
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Flora Peyvandi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Exudative Retinal Detachment Treatment in a Patient with Thrombotic Thrombocytopenic Purpura
Magali Sampo et al.
CASE REPORTS IN OPHTHALMOLOGY (2016)
Bilateral serous detachment of retina: an unusual mode of revelation of thrombotic thrombocytopenic purpura of favorable outcome with plasma exchange
Cherif Titah et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2014)
Pan-ocular hemorrhage in thrombotic thrombocytopenic purpura
Aniruddha Agarwal et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
Marie Scully et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center
Antoine Froissart et al.
CRITICAL CARE MEDICINE (2012)
Central retinal venous occlusion with co-existent thrombotic thrombocytopenic purpura and antiphospholipid syndrome
PT Murphy et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2003)
Share Paper
